As a greater proportion of patients survive their initial cardiac insult, medical systems
worldwide are being faced with an ever-growing need to understand the mechanisms …

Macrophages regulate tissue regeneration following injury. They can worsen tissue injury by
producing reactive oxygen species and other toxic mediators that disrupt cell metabolism …

Rationale: Umbilical cord–derived mesenchymal stem cells (UC-MSC) are easily accessible
and expanded in vitro, possess distinct properties, and improve myocardial remodeling and …

Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

Background: Although human mesenchymal stem cells (hMSCs) have been tested in
ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy …

Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …

Mounting evidence suggests that therapeutic cell and drug delivery strategies designed to
actively harness the regenerative potential of the inflammatory response have great …

The effects of cell therapy on heart regeneration in patients with chronic cardiomyopathy
have been assessed in several clinical trials. These trials can be categorized as those using …

Aims Cardiopoietic cells, produced through cardiogenic conditioning of patients'
mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure …

Myocardial ischemia-reperfusion injury (MIRI) is a serious threat to the health and lives of
patients without any effective therapy. Excessive production of reactive oxygen species …